Pharmaceutical company Suven Life Sciences said it has been granted product patents for a new compound being developed for the treatment of neurodegenerative diseases in Eurasia, Europe, South Korea and Sri Lanka. The compounds are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like the […]
Suven Life Sciences said it has obtained one product patent each from China and the US related to its 5-HT4 and 5 HT6 compounds. These patents add to the similar protections won in countries such as India, Korea, Singapore, Canada, Japan and Australia in the past. The Chinese patent has the number CN105814020 and the American […]
Pharma player Suven Life Sciences said it received two patents from Australia and one from Singapore for new drugs that can be used for the treatment of disorders associated with Neurodegenerative diseases. “The granted patents include the class of selective H3 Inverse agonists and 5HT 6 compounds respectively and are being developed as therapeutic agents […]
Suven Life Sciences Ltd said it was granted one patent each from Norway, South Korea and Singapore for drugs for the treatment of neurodegenerative diseases. The company said the patents relate to selective 5-HT 6 and 5HT 4 compounds, which are being developed as therapeutic agents for major depressive disorders and for the treatment of […]
Drug maker Suven Life Sciences Ltd said it secured more patents in India and South Korea for its drugs designed for treating neurodegenerative diseases. The India product patent is valid through 2029, while the Korean one is good for up to 2033, the company that focuses on neurological diseases said. “The granted claims of the […]
Suven Life Sciences Ltd said it has been granted one patent each in Canada and India for drugs for treating Neurodegenerative diseases. The Canadian patent 2932428 is valid through 2034 and the Indian patent 289123 is valid through 2028. The chemical entities are considered useful in the treatment of cognitive impairment associated with neurodegenerative disorders […]
Pharma company Suven Life Sciences Ltd said it received new patents in India, USA and Hong Kong for neurological drugs. The patents — one each in Hong Kong and the US and a couple in India — are valid through 2032, 2030 and 2034. “The granted claims of the patents include the class of selective […]
Suven Life Sciences Ltd said it was granted a patent by New Zealand authorities for “a class of selective 5-HT4 compounds” that are being developed to treat neurodegenerative diseases. The compounds are being explored for use in cases of Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, it said. The new […]
Suven Life Sciences Ltd said it got a patent from Australia and another from the US for a new molecule used for treating disorders associated with Neurodegenerative diseases. The ‘new chemical entity’ patent no 2014358652 from Australia is valid through 2032, while that from the US will last till 2034, the company said. The chemical […]
Drug manufacturer Suven Life Sciences Ltd said it got two product patents in India and Japan for to a new compound for the treatment of disorders associated with Neurodegenerative diseases. The patents are valid through 2026-2032. The granted claims include a class of selective 5-HT6 compounds and H3 inverse agonist compounds and are being developed as […]
Drug manufacturer Suven Life Sciences Ltd said it got three product patents from Canada, Europe & Hong Kong corresponding to new chemical entity for the treatment of disorders associated with Neurodegenerative diseases. The patents are valid through 2030-2032. According to the U.S. Food and Drug Administration, a new chemical entity (NCE) is a drug that […]
